Seeking Alpha

Michael Sacerdote

 
View as an RSS Feed
View Michael Sacerdote's Comments BY TICKER:
Latest  |  Highest rated
  • Herbalife: Can We Talk? The Vander Nat Paradox [View article]
    yes, MLMs are legal. So is adultery. That does not make them good or right.
    Jul 4 04:02 PM | 2 Likes Like |Link to Comment
  • Herbalife: Can We Talk? The Vander Nat Paradox [View article]
    There's an abiding myth that there's a distinction between "legitimate" MLMs and pyramid schemes; usually proponents of "legitimate" MLMs go on to cite Avon as an example. This distinction is pure fiction. The structure is inherently abusive. If there is any truth and justice in the world, MLMs should be eradicated with the full force and fury of the law.
    Jul 4 02:00 PM | 6 Likes Like |Link to Comment
  • Dominion Resources Black Warrior Trust Grossly Overvalued - 75% Downside, 90% Of Wells May Be Losing Money [View article]
    This is a fantastic article. Nicely done.
    Jun 30 09:22 AM | Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    You make illegitimate comparisons, like comparing 38-week data for squalamine+Lucentis against 24-week data for Fovista+Lucentis.

    I've taken the high road here. There's enough room for two.
    Jun 29 01:55 AM | Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    Actually, I got the numbers right as you can see in the figure I copied from Ohr's data release. I used Ohr's 24 week value to have an apples-to-apples comparison with Fovista's 24-week data.

    You spew a lot of poison. How about chilling out on a Saturday night?
    Jun 28 11:45 PM | 1 Like Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    Quick correction: when the Fovista concentration is 300 pM, half of the target will be bound.
    Jun 28 04:42 PM | Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    Proteins and nucleic acids often behave quite well together in solution. If you don't believe me, you might want to take a close look at the shocking happenings in your own cytoplasm.
    Jun 28 04:30 PM | Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    You don't understand Fovista's mechanism of action. See this article: http://bit.ly/TsJGbm

    Fovista binds to PDGF with a dissociation constant of 300 picomolar. At a concentration of 0.0000000003 molar, half of the Fovista will be bound to the target.
    Jun 28 04:05 PM | 1 Like Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    You might try counting the number of bearish articles where the author is long or bullish articles where the author is short. So far, I haven't seen any--here or anywhere else.

    I would also suggest that maybe there aren't a lot of bearish comments by people long a stock or bullish comments by people short a stock. Luckily, we have anonymous commenters who make no disclosures themselves to provide pure objectivity.
    Jun 28 03:19 PM | 1 Like Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    The drugs will mix either in the syringe barrel or in the vitreous humor. We've already done the experiment in the vitreous and nothing bad happened.

    As for compliance, the data on eye drops is well-attested in the literature. Please visit the link in the article. "Noncompliance" is not an accusation that patients are malevolently refusing to take their medications; instead, it's an acknowledgment that many patients face real-world obstacles to taking medicines on a regular basis. It's just reality.

    I agree that Adam F. was completely wrong in his characterization of the interim data. He missed the boat entirely.

    As for your attack on doctors, you are grossly and embarrassingly wrong if you think that the very large majority of physicians have anything other than their patients' best interests at heart. There are some incredibly bad apples, but most do right by patients to the very best of their abilities.
    Jun 28 03:07 PM | 1 Like Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    Differences of opinion are what make a market. I think that the failure to reduce intravitreal injections is a disaster for squalamine's commercial prospects. Management really blew it in their clinical trial design. They could have brought squalamine forward in ways that highlight its advantages, but instead advanced a program that highlights its disadvantages.

    In terms of time to market, fast-track status is not going to make a huge difference for squalamine. A 2-year trial will be needed for squalamine, just like for Fovista.
    Jun 28 02:56 PM | Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    You seem to have misread something. I haven't stated that I am long OHRP anywhere.
    Jun 28 02:47 PM | 1 Like Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    The top disclosure includes the "no positions" statement as unchangeable text when you click on a box in the article submission web app to indicate "may initiate a short position...over the next 72 hours." The "additional disclosure" has been a part of the article since I submitted it and has not been changed.
    Jun 28 01:41 PM | 2 Likes Like |Link to Comment
  • Phase II Calamity Dooms Ohr's Eye Drops [View article]
    If Ohr were able to show that a regimen of squalamine eye drops alone were superior to VEGF inhibitor injections or equivalent to VEGFi/Fovista injections, Ohr would be the undisputed winner. Alternatively, if Ohr had developed a bevacizumab/squalamine coformulation for intravitreal injection, that would have been a clear winner on the basis of price. However, those weren't the company's strategies. Instead, they fumbled and did a hybrid drops/injections strategy that will be less convenient to patients than injections. And I am confident that after Fovista is FDA-approved, people will use their common sense and co-inject Fovista and VEGF inhibitors in a single needle stick.
    Jun 28 01:30 PM | 1 Like Like |Link to Comment
  • Vertex: An Opportunity For Activist Investors [View article]
    It was a great day for kids with CF; all those extra birthday cakes they've earned will be especially sweet.
    Jun 25 06:17 PM | 1 Like Like |Link to Comment
COMMENTS STATS
220 Comments
304 Likes